Your session is about to expire
← Back to Search
Eribulin Mesylate for Bladder Cancer
Study Summary
This trial is testing whether adding the drug eribulin to standard chemotherapy drugs may work better in treating patients with metastatic urothelial cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 3 trial • 1276 Patients • NCT00337103Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there a lot of locations where this research is taking place within the state?
"There are a hundred participating centres in this study, like the Regional Cancer Center at Indian Path Community Hospital in Kingsport, Advanced Breast Care Centre PLLC in Warren, and Genesys Hurley Cancer Institute in Flint."
Can you tell me if Eribulin Mesylate has been used in other research studies?
"At the moment, there are a total of 1431 clinical studies underway that involve Eribulin Mesylate. Of these active investigations, 420 are in Phase 3. The concentration of research is based in Shanghai but this treatment is being trialled at 70,778 locations globally."
Could you speak to the side effects that come with Eribulin Mesylate?
"Eribulin Mesylate has gone through multiple rounds of testing and there is some evidence supporting efficacy, so it received a safety score of 3."
Share this study with friends
Copy Link
Messenger